Skye Bioscience, Inc./$SKYE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Skye Bioscience, Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Ticker
$SKYE
Sector
Primary listing
Employees
16
Headquarters
Website
SKYE Metrics
BasicAdvanced
$42M
-
-$1.29
2.66
-
Price and volume
Market cap
$42M
Beta
2.66
52-week high
$5.75
52-week low
$1.14
Average daily volume
399K
Financial strength
Current ratio
4.771
Quick ratio
4.222
Long term debt to equity
0.366
Total debt to equity
0.98
Profitability
EBITDA (TTM)
-53.218
Effective tax rate (TTM)
-0.01%
Management effectiveness
Return on assets (TTM)
-54.88%
Return on equity (TTM)
-94.31%
Valuation
Price to book
1.24
Price to tangible book (TTM)
1.24
Price to free cash flow (TTM)
-1.254
Free cash flow yield (TTM)
-79.77%
Free cash flow per share (TTM)
-1.045
Growth
Earnings per share change (TTM)
78.96%
3-year earnings per share growth (CAGR)
-40.40%
10-year earnings per share growth (CAGR)
-34.66%
SKYE News
AllArticlesVideos
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SKYE
Newsfile Corp15 hours ago
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
Newsfile Corp1 day ago
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SKYE
Business Wire1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Skye Bioscience, Inc. stock?
Skye Bioscience, Inc. (SKYE) has a market cap of $42M as of November 27, 2025.
What is the P/E ratio for Skye Bioscience, Inc. stock?
The price to earnings (P/E) ratio for Skye Bioscience, Inc. (SKYE) stock is 0 as of November 27, 2025.
Does Skye Bioscience, Inc. stock pay dividends?
No, Skye Bioscience, Inc. (SKYE) stock does not pay dividends to its shareholders as of November 27, 2025.
When is the next Skye Bioscience, Inc. dividend payment date?
Skye Bioscience, Inc. (SKYE) stock does not pay dividends to its shareholders.
What is the beta indicator for Skye Bioscience, Inc.?
Skye Bioscience, Inc. (SKYE) has a beta rating of 2.66. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.